Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Oct;130(10):561-6.
doi: 10.1007/s00432-004-0584-5. Epub 2004 Jul 29.

A phase II trial of FUdR in patients with advanced pancreatic cancer

Bach Ardalan  1 , Mayra Lima
Affiliations
Clinical Trial

A phase II trial of FUdR in patients with advanced pancreatic cancer

Bach Ardalan et al. J Cancer Res Clin Oncol. 2004 Oct.

Abstract

Purpose: This phase II study was conducted to assess the efficacy of fluorodeoxyuridine (FUdR) in patients with metastatic, advanced pancreatic cancer who had no previous chemotherapy.

Patients and methods: Twenty patients were enrolled in this single institution trial. The primary endpoint of this study was the assessment of overall survivorship. The secondary endpoints were to estimate the time to tumor progression and the assessment of toxicity in this cohort of patients. Treatment consisted of FUdR 150 mg/kg dissolved in 500 cc normal saline intravenous infusion over 24 h. Eight weeks of treatment constituted one course of chemotherapy. Tumor measurements were conducted at 8-weekly intervals.

Results: Four patients achieved partial response and 16 patients had stable disease. Median survival of patients treated with FUdR was 11.6 months with a range of 3-16 months. Median progression-free survival was 6 months. Overall, chemotherapy was well tolerated with low incidence of grade 3 or 4 toxicity.

Conclusions: Systemic chemotherapy with high dose FUdR administered on a weekly schedule has led to encouraging survival outcomes and improved quality of life as compared to previous phase II single agent chemotherapeutic trials.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time to progression for 20 pancreatic patients
Fig. 2
Fig. 2
Overall survival of 20 pancreatic cancer patients
See this image and copyright information in PMC

References

    1. Acute Pain Management Guideline Panel (1992) Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Agency for Health Care Policy and Research, Public Health Service. U.S. Department of Health and Human Services. AHCPR 92–0032, Rockville, MD, USA
    1. Ardalan B, Deng Z (1998) Comparison of cytotoxicity of fluoropyrimidines in human colon adenocarcinoma DLD-1 cells: with clinical implications. AACR 39:435
    1. Ardalan B, Cooney D, MacDonald J (1980) Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man. In: Garattini A, Hawking GF, Koplin IJ (eds) Advances in Pharmacology and Chemotherapy, vol. 17. Academic, New York, pp 289–321 - PubMed
    1. Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K (1994) Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer 74:1869–1873 - PubMed
    1. Ardalan B, Livingstone A, Franceschi D, Sridhar KS, Feun LG, Richman SP, Tripplett N, Sparling L (1997) phase II trial of high dose 24 h infusion of fluorodeoxyuridine (FUdR) in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemzar) (Abstract). Proc Am Soc Clin Oncol 16:282

Publication types

MeSH terms

Substances